Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,728.86
(
0.44%
)
US TECH 100
24,158.20
(
0.60%
)
Dow Jones
47,103.43
(
0.33%
)
Brent Oil
100.57
(
2.30%
)
Bitcoin
74,621.03
(
-0.30%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tinkershaw post# 119874

Wednesday, 05/11/2011 11:12:44 PM

Wednesday, May 11, 2011 11:12:44 PM

Post# of 257251

Directly substitutable vs. branded similars? I don't see how branded similar compete vs. a directly substitutable bio-identical.

It’ll be one or the other—we probably won’t see both kinds of FoB’s for the same reference drug in the same market.

…will there be direct substitutability or will MNTA and its partner need to market it like a branded?

MNTA’s stated goal is the former (#msg-26837144), but they have not completely ruled out being a player for the latter.

“The notion that there’s a Chinese Wall between sell-side analysts
and investment bankers may be the second-biggest piece of BS
ever promulgated in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now